Comparison of the efficacy and safety of irbesartan and olmesartan in patients with hypertension (EARTH study)

Clinical and Experimental Hypertension : CHE
Joji MoriiKeijiro Saku

Abstract

Fifty-four patients were randomly divided into irbesartan and olmesartan groups. Blood pressure (BP) was significantly decreased in all patients at 12 weeks. In particular, BP in patients who initially received irbesartan showed significant reductions. The equality of variance of BP in the irbesartan group was significantly smaller than that in the olmesartan group at 12 weeks. Blood concentrations of adiponectin were significantly increased in the irbesartan group at 12 weeks. Log [pentraxin-3] in the irbesartan group were significantly decreased. In conclusion, the ability of irbesartan to reduce BP is comparable to that of olmesartan with equivalent safety.

References

Feb 15, 2001·Circulation·M Burnier
Jan 14, 2004·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Shin-ichiro MiuraSadashiva S Karnik
Aug 18, 2004·Circulation·Danilo FliserUNKNOWN EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators
Jun 9, 2005·Hypertension·Ronald ClasenUlrich Kintscher
May 13, 2006·The Journal of Biological Chemistry·Shin-ichiro MiuraKeijiro Saku
Aug 31, 2006·Cardiovascular Drug Reviews·Kailash Prasad
Sep 19, 2006·Journal of the American College of Cardiology·Fumiyuki OtsukaHisao Ogawa
Dec 26, 2006·Circulation Journal : Official Journal of the Japanese Circulation Society·Atsushi IwataKeijiro Saku
Feb 28, 2007·Vascular Health and Risk Management·Hans R Brunner
Jan 29, 2008·The Journal of Pathology·As SavchenkoM Naito
Jul 18, 2008·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Satoru YamadaJunichiro Irie
May 23, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Makoto SugiharaKeijiro Saku
Jun 11, 2009·Clinical and Experimental Nephrology·Enyu ImaiSeiichi Matsuo
Nov 28, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Shin-Ichiro Miura, Keijiro Saku
Apr 9, 2010·Clinical and Experimental Hypertension : CHE·Yoshihiro KiyaKeijiro Saku
May 1, 2007·Journal of the American Society of Hypertension : JASH·Rhian M TouyzErnesto L Schiffrin
Jul 7, 2010·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Shin-ichiro MiuraKeijiro Saku
Jul 30, 2010·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Masahiro FujinoKeijiro Saku
Jun 17, 2011·Journal of cardiology·Takeshi SoekiMasataka Sata

❮ Previous
Next ❯

Citations

Nov 18, 2018·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Ryoko UmebayashiJun Wada
Feb 5, 2019·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Annabella Braschi
Aug 22, 2014·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Yuhei ShigaKeijiro Saku

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

Journal of the Renin-angiotensin-aldosterone System : JRAAS
Shin-Ichiro MiuraKeijiro Saku
Clinical and Experimental Hypertension : CHE
Shin-Ichiro Miura, Keijiro Saku
Hypertension Research : Official Journal of the Japanese Society of Hypertension
Shin-Ichiro MiuraKeijiro Saku
© 2021 Meta ULC. All rights reserved